Phase IV multicenter, prospective, open-label clinical trial of cenegermin (rhNGF) for stage 1 neurotrophic keratopathy (DEFENDO)
13/02/2024
Autori: Pedram Hamrah, Mina Massaro-Giordano, David Schanzlin, Edward Holland, Gregg Berdy, Giovanni Goisis, Georgea Pasedis & Flavio Mantelli
Pubblicato in:
Ophthalmology and Therapy